Mecasermin rinfabate: Insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3

Drugs in R and D

Volumn 6, Issue 2, 2005, Pages 120-127

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; MECASERMIN RINFABATE; ORPHAN DRUG; PLACEBO; PROTEINASE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; BODY HEIGHT; BURN; CACHEXIA; CHILD GROWTH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EUROPE; FOOD AND DRUG ADMINISTRATION; GROWTH DISORDER; GROWTH RATE; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LARON SYNDROME; LICENCE; META ANALYSIS; MYOTONIC DYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PATENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; SHORT STATURE; SIDE EFFECT; SURGERY; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

DRUGS, INVESTIGATIONAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECOMBINANT PROTEINS;

EID: 17044409041     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506020-00008     Document Type: Article

References (25)

1. Insmed Incorporated. Insured Acquires Manufacturing Facility from Baxter International. Media Release: 14 Apr 2004. Available from URL: http://www.insmed.com
2. Insmed Incorporated. Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories; Tzamal to Immediately Expand SomatoKine Named Patient Program. Media Release: 21 Oct 2004. Available from URL: http://www.insmed.com
3. Insmed Incorporated. Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months. Media Release: 20 Jul 2004. Available from URL: http://www.insmed.com
4. Insmed Incorporated. Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine. Media Release: 7 Oct 2002. Available from URL: http://www.insmed.com
5. Insmed Incorporated. Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes. Media Release: 29 Jan 2003. Available from URL: http://www.insmed.com
6. Insmed Incorporated. rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type 1 Diabetes. Media Release: 2 Dec 2003. Available from URL: http://www.insmed.com
7. Insmed Incorporated. Insmed Receives FDA Orphan Drug Designation For rhIGF-I/rhIGFBP-3, SomatoKine, for Extreme Insulin Resistance. Media Release: 15 Dec 2003. Available from URL: http://www.insmed.com
8. Insmed Incorporated. Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance. Media Release: 25 Oct 2004. Available from URL: http://www.insmed.com
9. Insmed Incorporated. Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine. Media Release: 9 Nov 2004. Available from URL: http://www.insmed.com
10. Insmed Incorporated. Insmed Obtains Patent Rights for Extreme Insulin Resistance From Fujisawa. Media Release: 26 Jan 2004. Available from URL: http://www.insmed.com
11. Insmed Incorporated. Insmed Provides Response to UK Patent Lawsuit. Media Release: 16 Feb 2005. Available from URL: http://www.insmed.com
12. Celtrix completes phase I studies of SomatoKine, demonstrating not only safety at high doses but also stimulation of bone and connective tissue metabolism. Inpharma 1070: 10, 18 Jan 1997
13. Insmed Incorporated. Insmed Presents Positive Data on Lead Drug Candidate at Endocrine Society Annual Meeting; Study Shows Advantages of Company's rhIGF-I/rhIGFBP-3 In Treating Growth Disorder. Media Release: 20 Jun 2003. Available from URL: http://www.insmed.com
14. Camacho-Hübner C, Storr HL, Miraki-Moud F, et al. Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome. 85th Annual Meeting of the Endocrine Society: 19 Jun 2003. Available from:URL: http://www.endo-society.org
15. Liao S, Hsieh F, Bright GM. Population pharmacokinetics of insulin-like growth factor-I in type I and II diabetic patients and in healthy adults. Diabetes 53 (Suppl. 2): 134-135, Jun 2004
16. Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. Journal of Clinical Endocrinology and Metabolism 87: 1593-1599, Apr 2002
17. Celtrix Pharmaceuticals Inc. Celtrix's SomatoKine demonstrates positive effects in diabetes patients; insulin usage lowered by 49%. Media Release [2 pages]: 25 Feb 1999
18. Saukkonen T, Amin R, Williams R, et al. Combined recombinant human insulin-like growth factor 1/insulin-like growth factor binding protein 3 suppresses growth hormone secretion and improves insulin sensitivity in adolescents with type 1 diabetes. Diabetes 52 (Suppl. 1): 132-133, Jun 2003
19. Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 89: 4634-4641, No. 9, Sep 2004
20. Insmed Incorporated. Insmed reports positive effects of SomatoKine in subjects with type 2 diabetes. Media Release [2 pages]: 8 Jan 2002. Available from URL: http://www.insmed.com
21. Rogol AD, Sommer A, Jacobson W, et al. A double-blind, randomized, placebo-controlled study to determine the dose response profile of rhIGF-I/rhIGFBP-3 in subjects with type 2 diabetes mellitus requiring insulin therapy. Diabetes 51 (Suppl. 2): 143 (plus poster), Jun 2002
22. Moses AC, Sommer A, Malcolm M, et al. Combination recombinant human insulin-like growth factor 1 and IGF binding protein 3 reduces insulin requirements and improves glycemic control in type 1 diabetes. Diabetes 48 (Suppl. 1): 93, May 1999
23. Initial clinical results reported on Celtrix's SomatoKine treatment for severe burns. BW HealthWire [online, 3 pages]: 5 May 1998. Available from URL: http://www.newspage.com
24. Celtrix's SomatoKline improves cardiac function in victims of burn trauma; results have potential widespread application for heart patients. BW HealthWire [online, 2 pages]: 20 Nov 1998. Available from URL: http://www.newspage.com
25. Celtrix Pharmaceuticals Inc. Celtrix's SomatoKine demonstrates significant effects in the treatment of trauma-induced protein wasting; results of phase II severe burns trial. Media Release [2 pages]: 10 Dec 1998